nach oben

Erschienen in:

01.07.2011 | Original Research Article

Sources of Information on Lymphoma Associated with Anti-Tumour Necrosis Factor Agents

Comparison of Published Case Reports and Cases Reported to the French Pharmacovigilance System

verfasst von: Héle`ne Théophile, Thierry Schaeverbeke, Ghada Miremont-Salamé, Abdelilah Abouelfath, Valentine Kahn, Françoise Haramburu, Bernard Bégaud, the French Pharmacovigilance Centres

Erschienen in: Drug Safety | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Background: Anti-tumour necrosis factor (TNF) agents, through their intense immunoregulatory effect, have been suspected to increase the risk of malignant lymphoma. However, the classical epidemiological approaches conducted over about the last 10 years have not totally succeeded in addressing the question of a causal or artifactual association. Therefore, the analysis of a substantial set of case reports, although usually considered as poorly generalizable to the general population, could be particularly informative. Two main sources of case reports in postmarketing settings are available; publications in medical journals and reports to pharmacovigilance systems.

Objective: The aim of the study was to compare the characteristics of case reports from both these sources in order to understand whether they provided the same information for the investigation of the causal link between lymphoma and anti-TNF agents.

Methods: All case reports of malignant lymphoma in patients treated with an anti-TNF agent published in MEDLINE and all reports to the French pharmacovigilance system up to 1 February 2010 were identified. Cases of malignant lymphoma identified in postmarketing surveillance from both sources were compared regarding the following variables: age, sex, anti-TNF agent involved, indication for use, type of lymphoma, prior or concomitant immunosuppressive drugs and time to onset of lymphoma.

Results: A total of 81 published case reports and 61 cases reported to the French pharmacovigilance system were compared. In published reports, patients were younger (p = 0.03) and more frequently receiving a first anti-TNF treatment (p = 0.03), particularly infliximab (p = 0.03). Conversely, in the pharmacovigilance system reports, a succession of different anti-TNFs (p = 0.03) and adalimumab (p< 0.0001) were more frequently reported. Lymphomas in patients treated with anti-TNF agents for Crohn’s disease were more prevalent in published cases than in pharmacovigilance reports (p< 0.0001), and in particular involved hepatosplenic T-cell lymphoma. Conversely, rheumatoid arthritis was the main indication for anti-TNF agents in pharmacovigilance reports (p = 0.01). Time to onset was markedly shorter in published cases (median 12 months) than in pharmacovigilance reports (median 30 months; p = 0.0001).

Conclusions: Characteristics of published cases and those reported to the French pharmacovigilance system differed markedly for all characteristics tested, except sex and the use of prior or concomitant immunosuppressive drugs. Published case reports favoured convincing arguments for drug causation whereas cases reported to the pharmacovigilance system were more disparate but could describe more accurately the reality of lymphoma occurrence in this particular population. These results argue for the use of the pharmacovigilance reports when case reports are used to investigate the causal link between lymphoma and anti-TNF agents at the population level. Data from cases notified to the French pharmacovigilance system did not indicate an increased risk of lymphoma during the early phase of anti-TNF treatment. To confirm this hypothesis, a study combining pharmacovigilance reports from several countries, or, if feasible, a cohort study both with a large sample size and a long duration of follow-up would be required.

Franklin JP, Symmons DP, Silman AJ. Risk of lymphoma in patients with RA treated with anti-TNFalpha agents. Ann Rheum Dis 2005; 64(5): 657–8PubMedCrossRef

Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50(6): 1740–51PubMedCrossRef

Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009; 68(5): 648–53PubMedCrossRef

Lichtenstein G, Cohen R, Feagan B, et al. Safety of infliximab and other Crohn’s disease therapies-TREAT registry data with nearly 15,000 patient-years of follow-up [abstract no. 490]. Gastroenterology 2006; 130: A71

Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview [online]. Available from URL: http://www.cochrane.org/cochrane-reviews [Accessed 2011 May 18]

Oxford Centre for Evidence-based Medicine. Levels of evidence [online]. Available from URL: http://wwwcebmnet/?o=1025 [Accessed 2010 Oct 11]

Girard C, Guillot B, Bessis D. Gastric MALT lymphoma in a patient receiving infliximab for psoriasis. Br J Dermatol 2008; 159(2): 497–8PubMedCrossRef

Dalle S, Balme B, Berger F, et al. Mycosis fungoides-associated follicular mucinosis under adalimumab. Br J Dermatol 2005; 153(1): 207–8PubMedCrossRef

Mahe E, Descamps V, Grossin M, et al. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003; 149(1): 170–3PubMedCrossRef

10.

Adams AE, Zwicker J, Curiel C, et al. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J Am Acad Dermatol 2004; 51(4): 660–2PubMedCrossRef

11.

Aksu K, Cagirgan S, Ozsan N, et al. Non-Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int. Epub 2009 Dec 16

12.

Bai M, Katsanos KH, Economou M, et al. Rectal Epstein-Barr virus-positive Hodgkin’s lymphoma in a patient with Crohn’s disease: case report and review of the literature. Scand J Gastroenterol 2006; 41(7): 866–9PubMedCrossRef

13.

Berthelot C, Cather J, Jones D, et al. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. Clin Lymphoma Myeloma 2006; 6(4): 329–32PubMedCrossRef

14.

Bickston SJ, Lichtenstein GR, Arseneau KO, et al. The relationship between infliximab treatment and lymphoma in Crohn’s disease. Gastroenterology 1999; 117(6): 1433–7PubMedCrossRef

15.

Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46(12): 3151–8PubMedCrossRef

16.

Bucher C, Degen L, Dirnhofer S, et al. Biologics in inflammatory disease: infliximab associated risk of lymphoma development. Gut 2005; 54(5): 732–3PubMedCrossRef

17.

Chuang GS, Wasserman DI, Byers HR, et al. Hypopigmented T-cell dyscrasia evolving to hypopigmented mycosis fungoides during etanercept therapy. J Am Acad Dermatol 2008; 59 (5 Suppl): S121–2PubMedCrossRef

18.

Colombel JF, Loftus Jr EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126(1): 19–31PubMedCrossRef

19.

Dauendorffer JN, Rivet J, Allard A, et al. Sezary syndrome in a patient receiving infliximab for ankylosing spondylitis. Br J Dermatol 2007; 156(4): 742–3PubMedCrossRef

20.

Drini M, Prichard PJ, Brown GJ, et al. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn’s disease. Med J Aust 2008; 189(8): 464–5PubMed

21.

Ganguly S. Leukemic phase of follicular lymphoma after treatment with etanercept in a patient with psoriasis. Am J Clin Dermatol 2009; 10(2): 125–6PubMedCrossRef

22.

Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64(5): 699–703PubMedCrossRef

23.

Imundo L. Hodgkin’s lymphoma associated with anti-TNF use in juvenile idiopathic arthritis: supplemental case report [letter]. J Rheumatol 2008; 35(8): 1681PubMed

24.

Koens L, Senff NJ, Vermeer MH, et al. Cutaneous gamma/delta T-cell lymphoma during treatment with etanercept for rheumatoid arthritis. Acta Derm Venereol 2009; 89(6): 653–4PubMedCrossRef

25.

Komatsuda A, Wakui H, Nimura T, et al. Reversible in-fliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. Mod Rheumatol 2008; 18(3): 315–8PubMedCrossRef

26.

Lafaille P, Bouffard D, Provost N. Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept. Arch Dermatol 2009; 145(1): 94–5PubMedCrossRef

27.

Ljung BM, Char D, Miller TR, et al. Intraocular lymphoma: cytologic diagnosis and the role of immunologic markers. Acta Cytol 1988; 32(6): 840–7PubMed

28.

Losco A, Gianelli U, Cassani B, et al. Epstein-Barr virusassociated lymphoma in Crohn’s disease. Inflamm Bowel Dis 2004; 10(4): 425–9PubMedCrossRef

29.

Lourari S, Prey S, Livideanu C, et al. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases. J Eur Acad Dermatol Venereol 2009; 23(8): 967–8PubMedCrossRef

30.

Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009; 48(3): 386–8PubMedCrossRef

31.

Michot C, Costes V, Gerard-Dran D, et al. Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritis. Br J Dermatol 2009; 160(4): 889–90PubMedCrossRef

32.

Nakashima C, Tanioka M, Takahashi K, et al. Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate. Clin Exp Dermatol 2008; 33(4): 437–9PubMedCrossRef

33.

Podolsky DK, Gonzalez RG, Hasserjian RP. Case records of the Massachusetts General Hospital — case 8–2006: a 71-year-old woman with Crohn’s disease and altered mental status. N Engl J Med 2006; 354(11): 1178–84PubMedCrossRef

34.

Quartuccio L, De Re V, Fabris M, et al. Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. Haematologica 2006; 91(5): 691–4PubMed

35.

Redmond M, Quinn J, Murphy P, et al. Plasmablastic lymphoma presenting as a paravertebral mass in a patient with Crohn’s disease after immunosuppressive therapy. J Clin Pathol 2007; 60(1): 80–1PubMedCrossRef

36.

Roddy E, Courtney PA, Morris A. Non-Hodgkin’s lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology (Oxford) 2002; 41(10): 1194–5CrossRef

37.

Sanli Y, Adalet I, Turkmen C, et al. Primary lymphoma of the small bowel detected with red blood cell scintigraphy. Clin Nucl Med 2005; 30(7): 490–1PubMedCrossRef

38.

Schwartz LK, Kim MK, Coleman M, et al. Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4(8): 1030–4PubMedCrossRef

39.

Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005; 40(2): 220–2PubMedCrossRef

40.

Thonhofer R, Gaugg M, Kriessmayr M, et al. Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment. Ann Rheum Dis 2005; 64(7): 1098–9PubMedCrossRef

41.

Yildirim-Toruner C, Kimura Y, Rabinovich E. Hodgkin’s lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. J Rheumatol 2008; 35(8): 1680–1PubMed

42.

Zeidan A, Sham R, Shapiro J, et al. Hepatosplenic T-cell lymphoma in a patient with Crohn’s disease who received infliximab therapy. Leuk Lymphoma 2007; 48(7): 1410–3PubMedCrossRef

43.

Ziakas PD, Giannouli S, Tzioufas AG, et al. Lymphoma development in a patient receiving anti-TNF therapy. Haematologica 2003; 88(7): ECR25PubMed

44.

Haramburu F, Begaud B, Pere JC. Comparison of 500 spontaneous and 500 published reports of adverse drug reactions. Eur J Clin Pharmacol 1990; 39(3): 287–8PubMedCrossRef

45.

Rossi AC, Knapp DE. Discovery of new adverse drug reactions: a review of the Food and Drug Administration’s spontaneous reporting system. JAMA 1984; 252(8): 1030–3PubMedCrossRef

46.

De Backer TL, Vander Stichele RH, Van Bortel LM. Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication. Drug Saf 2009; 32(4): 283–91PubMedCrossRef

47.

Meyboom RH, Star K, Bate J, et al. TNF-alpha inhibitors and leukaemia: international pharmacovigilance reports. Drug Saf 2008; 31(5): 445–7PubMedCrossRef

48.

Baecklund E, Askling J, Rosenquist R, et al. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 2004; 16(3): 254–61PubMedCrossRef

49.

Thomas E, Brewster DH, Black RJ, et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000; 88(3): 497–502PubMedCrossRef

50.

Haute Autorité de Santé. Commission de la transparence: remicade Crohn enfant_CT 6220 [online]. Available from URL: http://wwwhas-santefr/portail/jcms/c_765718/avis-remicade-ct-6220 [Accessed 2010 Dec 23]

51.

Arnaiz JA, Carne X, Riba N, et al. The use of evidence in pharmacovigilance: case reports as the reference source for drug withdrawals. Eur JClin Pharmacol 2001; 57(1): 89–91CrossRef

52.

Hochberg AM, Hauben M. Time-to-signal comparison for drug safety data-mining algorithms vs traditional signaling criteria. Clin Pharmacol Ther 2009; 85(6): 600–6PubMedCrossRef

53.

Venning GR. Identification of adverse reactions to new drugs — IV: verification of suspected adverse reactions. BMJ (Clin Res Ed) 1983; 286(6364): 544–7CrossRef

54.

Hochberg AM, Pearson RK, O’Hara DJ, et al. Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System. Drug Saf 2009; 32(2): 137–46PubMedCrossRef

55.

Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. Br J Clin Pharmacol 2004; 57(5): 616–21PubMedCrossRef

56.

Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010; 69(2): 400–8PubMedCrossRef

57.

Tubach F, Salmon-Ceron D, Ravaud P, et al. The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy. Joint Bone Spine 2005; 72(6): 456–60PubMedCrossRef

58.

Article R.5144.19 du Code de la Santé publique [online]. Available from URL: wwwsantegouvfr/cerfa/efindes/abvitotpdf [Accessed 2010 Oct 11]

Titel: Sources of Information on Lymphoma Associated with Anti-Tumour Necrosis Factor Agents
Comparison of Published Case Reports and Cases Reported to the French Pharmacovigilance System
verfasst von: Héle`ne Théophile
Thierry Schaeverbeke
Ghada Miremont-Salamé
Abdelilah Abouelfath
Valentine Kahn
Françoise Haramburu
Bernard Bégaud
the French Pharmacovigilance Centres
Publikationsdatum: 01.07.2011
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 7/2011
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/11590200-000000000-00000

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2011

The Risk of Ischaemic Colitis in Irritable Bowel Syndrome Patients Treated with Serotonergic Therapies

Adherence to Biochemical Monitoring Recommendations in Patients Starting with Renin Angiotensin System Inhibitors

Electronic Drug Interaction Alerts in Ambulatory Care

Risk of Hospitalization for Hip Fracture and Pneumonia Associated with Antipsychotic Prescribing in the Elderly

Association between Leukotriene-Modifying Agents and Suicide

Drug Prescribing Before and During Pregnancy in South West France